



## GUIDELINES FOR PROVIDING PUBLIC COMMENT TO THE MAINECARE DUR COMMITTEE

MaineCare encourages public input into the Preferred Drug List (PDL) process. The Drug Utilization Review (DUR) Committee meeting agendas will be posted at [www.mainearepdl.org](http://www.mainearepdl.org) prior to the meetings. The public may sign up to address the committee during the Public Comments portion of the agenda either by emailing Carla Quinlivan at [carla\\_quinlivan@optum.com](mailto:carla_quinlivan@optum.com) and Mike Ouellette at [michael\\_ouellette@optum.com](mailto:michael_ouellette@optum.com) ahead of the meeting or signing up as a walk-in speaker at the beginning of the meeting. Walk-in speakers will have an opportunity to speak to the committee in the order of the sign-in and after the scheduled speakers are finished. When addressing the committee, speakers will provide the committee with their name, the name of their organization, the speaker's relationship to the organization and the topic area to be covered.

### Drug Manufacturer Representatives

- Limit comments to 3 minutes or less.
- Comments should include either an individual product or the entire product line.
- Focus on clinical information that may set the product apart from others in the same PDL category.
- Concise summaries of clinical information, limited to one side of one page, may be submitted to Carla Quinlivan, [carla\\_quinlivan@optum.com](mailto:carla_quinlivan@optum.com) and Mike Ouellette, [michael\\_ouellette@optum.com](mailto:michael_ouellette@optum.com), for distribution to the committee members.

Thank you for your cooperation.

### SUMMARY

1. Sign up to speak.
2. Provide a concise synopsis of the product (one side of one page) and submit to [carla\\_quinlivan@optum.com](mailto:carla_quinlivan@optum.com) and [michael\\_ouellette@optum.com](mailto:michael_ouellette@optum.com) or bring copies to the meeting (recommend minimum 15).
3. Speakers must provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area.
4. Limit speaking time to less than three minutes for their individual product or entire product line.
5. Direct comments toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results etc.
6. Audiovisual presentations are not allowed due to time constraints.